Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
StockNews.AI · 3 hours
AI Summary
Pharvaris presented EAACI 2026 data for deucrictibant, highlighting End of Progression as a prespecified efficacy endpoint and strong on-demand performance. RAPIDe-3 shows rapid symptom relief and high single-dose efficacy, while CHAPTER-1 long-term data indicate durable prophylaxis with meaningful HRQoL gains. An NDA submission is anticipated in 2026, setting up near-term regulatory catalysts and potential market expansion.
Sentiment Rationale
Clear data elegance (EoP, rapid onset), dual use (on-demand and prophylaxis), strong CV safety, and imminent NDA timing create multiple near-term catalysts and potential re-rating.
Trading Thesis
Positive EAACI data and NDA timing create near-term upside for PHVS as a multi-faceted HAE therapy platform.
Market-Moving
- RAPIDe-3 shows rapid onset and high single-dose efficacy, a key differentiator.
- CHAPTER-1 long-term prophylaxis data imply durable market potential.
- NDA timing anticipated in 2026 provides near-term regulatory catalyst.
- Favorable cardiovascular safety data reduce regulatory and safety risk.
Key Facts
- EAACI 2026 data show End of Progression endpoint and rapid response for deucrictibant.
- RAPIDe-3: onset 1.28h; full relief ~11.95h; 83% single-dose efficacy.
- EoP median 17.47 min vs 228.67; 92.8% hit EoP within 12h.
- Long-term CHAPTER-1: prophylaxis reduces attacks ~92%; ~100% well-controlled Week 62+.
- CV safety favorable across ~570 patients; no QT prolongation or major cardiac events.
Companies Mentioned
- Pharvaris (PHVS): Positive EAACI data reinforces deucrictibant's differentiated profile; supports NDA catalyst.
Industry News
Industry News; profiles a late-stage biotech's clinical/regulatory milestones and their potential market impact.